

Product information



Information about other products is available at: www.IBL-America.com

ImmunoGuide®

Instructions for Use

Bevacizumab ELISA

Enzyme immunoassay for the determination
of free Bevacizumab in serum and plasma

REF: TM09010




12X8



2-8°C

For Research Use Only - Not for Use in Diagnostic Procedures

 Manufactured for
Immuno-Biological Laboratories Inc. (IBL-America)

8201 Central Avenue NE,
Suite P Minneapolis,
MN 55432 USA

Tel: 763-780-2955 Toll Free: 1-888-523-1246

www.ibl-america.com

<u>Contents</u>	<u>Page</u>
1. Intended Use	2
2. Summary and Explanation	2
3. Principle of the Test	2
4. Warnings and Precautions	2
5. Storage and Stability of the Kit	3
6. Specimen Collection, Handling and Storage	3
7. Contents of the Kit	4
8. Materials Required but not Supplied	4
9. Procedure Notes	4
10. Pre-Test Setup Instructions	5
10.1. Preparation of Components	5
10.2. Dilution of Standards and Samples	6
11. Test Procedure	6
11.1. General Remarks	6
11.2. Assay Procedure	7
11.3. Quality Control	8
11.4. Calculation of Results	8
12. Assay characteristics	9
12.1. Specificity	9
12.2. Sensitivity	10
12.3. Precision	10
12.4. Recovery	10
13. Automation	10
14. References	10

1. INTENDED USE

Enzyme immunoassay for the determination of free Bevacizumab in serum and plasma. For research use only - not for use in diagnostic procedures.

2. SUMMARY AND EXPLANATION

The drug Bevacizumab (trade name Avastin[®]) is a recombinant human IgG1:κ monoclonal antibody specific for all human vascular endothelial growth factor-A (VEGF-A) isoforms and it has been approved by the FDA as a first-line treatment for metastatic colorectal cancer in combination with chemotherapy. Furthermore, VEGF is implicated in intraocular neovascularization associated with diabetic retinopathy and age-related macular degeneration.

Identification of biomarkers for (non-)response and risk factors for adverse drug reactions that might be related to serum concentrations and maintaining the effective concentration of Bevacizumab in order to potentially avoid some side effects with a reliable method might be beneficial.

3. PRINCIPLE OF THE TEST

This ELISA assay is based on sandwich type ELISA. Diluted standards and samples (serum or plasma) are incubated in the microtiter plate coated with recombinant human vascular endothelial growth factor-A (rhVEGF-A). After incubation, the wells are washed. A horseradish peroxidase (HRP) conjugated anti-human IgG monoclonal antibody is added and binds to the Fc part of Bevacizumab pre-captured by the rhVEGF-A on the surface of the wells. Following incubation, the wells are washed and the bound enzymatic activity is detected by addition of chromogen-substrate. The colour developed is proportional to the amount of Bevacizumab in the sample or standard. Results of samples can be determined by using the standard curve.

4. WARNINGS AND PRECAUTIONS

1. Before starting the assay, read the instructions completely and carefully. Use the valid version of the package insert provided with the kit. Be sure that everything is understood. For further information (clinical background, test performance, automation protocols, alternative applications, literature, etc.) please refer to the local distributor.
2. In case of severe damage of the kit package, please contact **IBL-America** or your supplier in writing, latest one week after receiving the kit. Do not use damaged components in test runs, but keep safe for complaint related issues.
3. Obey lot number and expiry date. Do not mix reagents of different lots. Do not use expired reagents.
4. Follow good laboratory practice and safety guidelines. Wear lab coats, disposable latex gloves and protective glasses where necessary.
5. Reagents of this kit containing hazardous material may cause eye and skin irritations. See MATERIALS SUPPLIED and labels for details.

6. Chemicals and prepared or used reagents have to be treated as hazardous waste according the national biohazard safety guidelines or regulations.
7. Avoid contact with Stop solution. It may cause skin irritations and burns.
8. If any component of this kit contains human serum or plasma it is indicated and if so, it have been tested and were found to be negative for HIV I/II, HBsAg and HCV. However, the presence of these or other infectious agents cannot be excluded absolutely and therefore reagents should be treated as potential biohazards in use and for disposal.
9. Some reagents contain preservatives. In case of contact with eyes or skin, flush immediately with water.

5. STORAGE AND STABILITY OF THE KIT

The kit is shipped at ambient temperature and should be stored at 2-8°C. Keep away from heat or direct sun light. The storage and stability of specimen and prepared reagents is stated in the corresponding chapters. The microtiter strips are stable up to the expiry date of the kit in the broken, but tightly closed bag when stored at 2–8°C.

6. SPECIMEN COLLECTION, HANDLING AND STORAGE

Serum, Plasma (EDTA, Heparin)

The usual precautions for venipuncture should be observed. It is important to preserve the chemical integrity of a blood specimen from the moment it is collected until it is assayed. Do not use grossly hemolytic, icteric or grossly lipemic specimens. Samples appearing turbid should be centrifuged before testing to remove any particulate material.

Storage:	2-8°C	≤-20°C (Aliquots)	Keep away from heat or direct sun light Avoid repeated freeze-thaw cycles
Stability:	3 d	6 mon	

7. CONTENTS OF THE KIT

QUANTITY	COMPONENT
1 x 12 x 8	Microtiter ELISA Plate Break apart strips coated with recombinant human vascular endothelial growth factor-A (rhVEGF-A).
5 x 0.5 mL	Bevacizumab Standards A-E, Concentrate (10X) 2000; 600; 200; 60; and 0 ng/mL Used for construction of the standard curve. Contains Bevacizumab, proteins, preservative and stabilizer.
1 x 12 mL	Assay Buffer Blue colored. Ready to use. Contains proteins and preservative.
1 x 60 mL	Dilution Buffer, Concentrate (5X) Contains orange dye, proteins and preservative.
1 x 12 mL	Enzyme Conjugate Red colored. Ready to use. Contains horseradish peroxidase(HRP)-conjugated anti-human IgG mouse monoclonal antibody, Proclin [®] and stabilizers.
1 x 12 mL	TMB Substrate Solution Ready to use. Contains 3,3',5,5'-Tetramethylbenzidine (TMB).
1 x 12 mL	Stop Solution Ready to use. 1 N Hydrochloric acid (HCl).
1 x 50 mL	Wash Buffer, Concentrate (20x) Contains buffer, Tween [®] 20 and Kathon [™] .
2 x 1	Adhesive Seal For sealing microtiter plate during incubation.

8. MATERIALS REQUIRED BUT NOT SUPPLIED

1. Micropipettes (< 3% CV) and tips to deliver 5-1000 μ L.
2. Bidistilled or deionised water and calibrated glasswares (e.g. flasks or cylinders).
3. Wash bottle, automated or semi-automated microtiter plate washing system.
4. Microtiter plate reader capable of reading absorbance at 450 nm (reference wavelength at 600-650 nm is optional).
5. Absorbent paper towels, standard laboratory glass or plastic vials, and a timer.

9. PROCEDURE NOTES

1. Any improper handling of samples or modification of the test procedure may influence the results. The indicated pipetting volumes, incubation times, temperatures and pre-treatment steps have to be performed strictly according to the instructions. Use calibrated pipettes and devices only.
2. Once the test has been started, all steps should be completed without interruption. Make sure that required reagents, materials and devices are

prepared readily at the appropriate time. Allow all reagents and specimens to reach room temperature (20-25°C) and gently swirl each vial of liquid reagent and sample before use. Mix reagents without foaming.

3. Avoid contamination of reagents, pipettes and wells/tubes. Use new disposable plastic pipette tips for each reagent, standard or specimen. Do not interchange the caps of vials. Always cap not used vials. Do not reuse wells or reagents.

4. Use a pipetting scheme to verify an appropriate plate layout.

5. Incubation time affects results. All wells should be handled in the same order and time sequences. It is recommended to use an 8-channel Micropipettor for pipetting of solutions in all wells.

6. Microplate washing is important. Improperly washed wells will give erroneous results. It is recommended to use a multichannel pipette or an automatic microplate washing system. Do not allow the wells to dry between incubations. Do not scratch coated wells during rinsing and aspiration. Rinse and fill all reagents with care. While rinsing, check that all wells are filled precisely with Wash Buffer, and that there are no residues in the wells.

7. Humidity affects the coated wells. Do not open the pouch until it reaches room temperature. Unused wells should be returned immediately to the resealed pouch including the desiccant.

10. PRE-TEST SETUP INSTRUCTIONS

10.1. Preparation of Components*

Dilute/ dissolve	Component		Diluent	Relation	Remarks	Storage	Stability
10 mL	Wash Buffer	up to 200mL	Distilled Water	1:20	Warm up at 37°C to dissolve crystals. Mix vigorously.	2-8 °C	4 w
10 mL	Dilution Buffer	up to 50mL	Distilled Water	1:5		2-8 °C	4 w


* Prepare Wash and Dilution Buffers before starting the assay procedure.

10.2. Dilution of Standards and Samples

The dilutions depicted below are examples of how to obtain final 1:1000 dilution. Standards and samples should be properly diluted as homogenous mixture before starting the assay procedure. It is recommended mixing the standards and samples well to homogenous solution at each dilution step. We are recommending that each laboratory determines the best initial dilution for their samples in order to minimize retesting.

1. 20 μL of standard added to 180 μL of 1X dilution buffer, giving the total volume of 200 μL and a dilution of 1:10.
2. 10 μL of sample added to 90 μL of 1X dilution buffer, giving the total volume of 100 μL and a dilution of 1:10.
3. 10 μL of 1:10 diluted sample added to 990 μL of 1X dilution buffer, giving the total volume of 1000 μL and a dilution of 1:1000. This second dilution should not be done with the standards.
4. Samples with a drug concentration above the measuring range should be rated as ">highest standard". The result should not be extrapolated. The sample in question should be further diluted with 1X Dilution Buffer and then retested.

Standard/Sample Dilution



11. TEST PROCEDURE

11.1. GENERAL REMARKS

- 11.1.1. Before performing the assay, samples and assay kit should be brought to room temperature (about 30 minutes beforehand) and ensure the homogeneity of the solution.
- 11.1.2. All Standards should be run with each series of unknown samples.
- 11.1.3. Standards should be subject to the same manipulations and incubation times as the samples being tested.
- 11.1.4. All steps of the test should be completed without interruption.

11.1.5. Use new disposable plastic pipette tips for each reagent, standard or specimen in order to avoid cross contamination.

11.1.6. The total pipetting time needed for dispensing all samples into the wells should not exceed 5 minutes. If this is difficult to achieve the samples should be pre-dispensed in a separate neutral polypropylene microplate and then transferred into the reaction ELISA plate by a multi channel pipette.

11.2. ASSAY PROCEDURE

1.	Pipette 100 μL of Assay Buffer into each of the wells to be used.
2.	Pipette 50 μL of each 1:10 Diluted Standard and 1:1000 Diluted Samples into the respective wells of the microtiter plate. Bubble formation during the pipetting of standards and samples must be avoided. <u>Wells</u> A1: Standard A B1: Standard B C1: Standard C D1: Standard D E1: Standard E F1 and so on: Samples (Serum/Plasma)
3.	Cover the plate with adhesive seal. Shake plate carefully by tapping several times. Incubate the plate on a bench top for 60 min at room temperature (RT, 20-25°C).
4.	Remove adhesive seal. Aspirate or decant the incubation solution. Wash the plate 5 X 350 μL of Diluted Wash Buffer per well. Remove excess solution by tapping the inverted plate on a paper towel.
5.	Pipette 100 μL of Enzyme Conjugate (HRP-anti human IgG mAb) into each well.
6.	Cover plate with adhesive seal. Shake plate carefully by tapping several times. Incubate the plate on a bench top for 30 min at RT.
7.	Remove adhesive seal. Aspirate or decant the incubation solution. Wash the plate 5 X 350 μL of Diluted Wash Buffer per well. Remove excess solution by tapping the inverted plate on a paper towel.
8.	Pipette 100 μL of Ready-to-Use TMB Substrate Solution into each well.
9.	Incubate 15 min at RT. Avoid exposure to direct sunlight.
10.	Stop the substrate reaction by adding 100 μL of Stop Solution into each well. Briefly mix contents by gently shaking the plate. Color changes from blue to yellow.
11.	Measure optical density (OD) with a photometer at 450 nm (Reference at OD620 nm is optional) within 15 min after pipetting the Stop Solution.

11. 3. QUALITY CONTROL

The test results are only valid if the test has been performed following the instructions. Moreover the user must strictly adhere to the rules of GLP (Good Laboratory Practice) or other applicable standards/laws. All standards/controls must be found within the acceptable ranges as stated above and/or label. If the criteria are not met, the run is not valid and should be repeated. In case of any deviation, the following technical issues should be reviewed: Expiration dates of (prepared) reagents, storage conditions, pipettes, devices, incubation conditions and washing methods.


11. 4. CALCULATION OF RESULTS

A standard curve should be constructed using the standard concentration (X-axis) versus the OD450 (or OD450/620) values (Y-axis). This can be done manually using graph paper or with a computer program. Concerning the data regression by computer, it is recommended to primarily use the “4 Parameter Logistic (4PL)” or alternatively the “point-to-point calculation”. In case of manual plot there are 2 options: Semilog graph (see Fig. A) or linear graph (see Fig. B). Semilog graph paper is available at <http://www.papersnake.com/logarithmic/semilogarithmic/>. The concentration of the samples can be read from this standard curve as follows. Using the absorbance value for each sample, determine the corresponding concentration of the drug from the standard curve. This value always has to be multiplied by the individual dilution factor. If any diluted sample is reading greater than the highest standard, it should be further diluted appropriately with 1X Dilution Buffer and retested. Also this second dilution has to be used for calculation of the final result. We are recommending that each laboratory determines the best initial dilution for their samples in order to minimize retesting.

Typical Calibration Curve

(Just an example. Do not use it for calculation!)

1:10 Diluted Standard	A	B	C	D	E
Concentration (ng/mL)	200	60	20	6	0
Mean OD450/620 nm	2.325	0.815	0.322	0.112	0.020



12. ASSAY CHARACTERISTICS

12.1. SPECIFICITY

There is no cross reaction with native serum immunoglobulins. Thirty seven native human sera were screened and all produced OD450/620 nm lower than 0.112. Other therapeutic antibodies (Omalizumab, Golimumab, Infliximab, Trastuzumab, Rituximab, Etanercept, Adalimumab and Tocilizumab) are also tested at the concentrations up to 400 µg/mL and observed that there are no cross reactions (OD 450/620nm values were less than 0.112). In addition, interference of Ranibizumab, binds to the same antigen VEGF-A, was tested at 25 ng/mL (nearly ten times of the serum C_{max} of Ranibizumab) and no measurable inhibition was observed.

12.2. SENSITIVITY

The lowest detectable level that can be clearly distinguished from the zero standard is 2 ng/mL (zero standard +2SD read from the curve) under the above-described conditions. Analytical sensitivity is 2 ng/mL, and corresponding to the detection limit (limit of quantification) of 2 µg/mL for undiluted clinical samples because the serum or plasma samples are instructed to be diluted at 1:1000 before starting the assay.

12.3. PRECISION

Intra-assay CV: <10%.

Inter-assay CV: <10%.

12.4. RECOVERY

Recovery rate was found to be >95% with native human serum and plasma samples when spiked with exogenous Bevacizumab at 200 µg/mL, 60 µg/mL, 20 µg/mL or 6 µg/mL.

13. AUTOMATION

The *ImmunoGuide* Bevacizumab ELISA (mAb-based) is suitable also for being used by an automated ELISA processor.

14. REFERENCES

1. Li J, Gupta M; Jin D, Xin Y, Visich J, Allison DE, Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stag II and III carcinoma of the colon, *Cancer Chemother Pharmacol*, 2013; 71: 575–580.
2. Panoilia E, Schindler E, Samantas E, Aravantinos G, Kalofonos HP, Christodoulou C, Patrinos GP, Friberg LE, Sivolapenko G, A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients, *Cancer Chemother Pharmacol*. 2015; 75:791–803.
3. Knight B, Rassam D, Liao S, Ewesuedo R. A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers, *Cancer Chemother Pharmacol*. 2016;77:839–846.
4. Azzopardi N, Dupuis-Girod S, Ternant D, Fargeton AE, Ginon I, et al., Dose – response relationship of bevacizumab in hereditary hemorrhagic telangiectasia, *mAbs*. 2015; 7 (3): 630–637.
5. Han K, Peyret T, Quartino A, Gosselin NH, Gururangan S, Daw NC, Navid F, Jin J, Allison DE. Bevacizumab dosing strategy in pediatric cancer patients based on population pharmacokinetic analysis with external validation. *Br J Clin Pharmacol*. 2015 Sep 7. doi: 10.1111/bcp.12778.
6. Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, Couvillion S, Nasir MA, Rabena MD, Le K, Maia M, Visich JE. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. *Br J Ophthalmol*. 2014 Dec;98(12):1636-41.

7. Bunni J, Shelley-Fraser G, Stevenson K, Oltean S, Salmon A, Harper SJ, Carter JG, Bates DO. Circulating levels of anti-angiogenic VEGF-A isoform (VEGF-A_{xxx}b) in colorectal cancer patients predicts tumour VEGF-A ratios. *Am J Cancer Res.* 2015;5(6):2083-9.
8. Imbs DC, Négrier S, Cassier P, Hollebecque A, Varga A, Blanc E, Lafont T, Escudier B, Soria JC, Pérol D, Chatelut E. Pharmacokinetics of pazopanib administered in combination with bevacizumab. *Cancer Chemother Pharmacol.* 2014 Jun;73(6):1189-96.
9. Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E, Lopez PF. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). *Retina.* 2012 Mar;32(3):434-57.
10. Li Q, Yan H, Zhao P, Yang Y, Cao B. Efficacy and Safety of Bevacizumab Combined with Chemotherapy for Managing Metastatic Breast Cancer: A Meta-Analysis of Randomized Controlled Trials. *Sci Rep.* 2015 Oct 27;5:15746. doi: 10.1038/srep15746.
11. Tang N, Guo J, Zhang Q, Wang Y, Wang Z. Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis. *Oncotarget.* 2015 Oct 20. doi: 10.18632/oncotarget.6184.
11. Ogata H, Kikuchi Y, Natori K, et al. Liver Metastasis of a Triple-Negative Breast Cancer and Complete Remission for 5 Years After Treatment With Combined Bevacizumab/Paclitaxel/Carboplatin: Case Report and Review of the Literature. *Medicine (Baltimore).* 2015 Oct;94(42):e1756. doi: 10.1097/MD.0000000000001756.
12. Guo J, Glass JO, McCarville MB, Shulkin BL, Daryani VM, Stewart CF, Wu J, Mao S, Dwek JR, et al. Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI. *Br J Cancer.* 2015;113(9):1282-8.
13. Varol U, Oktay E, Yildirim M, Surmeli ZG, Dirican A, Meydan N, Karaca B, Karabulut B, Uslu R. Tumor characteristics and metastatic sites may predict bevacizumab efficacy in the first-line treatment of metastatic colorectal cancer. *Mol Clin Oncol.* 2014;2(1):166-170.
14. Ba J, Peng RS, Xu D, Li YH, Shi H, Wang Q, Yu J. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis. *Drug Des Devel Ther.* 2015;9:5397-405.
15. Li X, Huang R, Xu Z. Risk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: a Systematic Review and Meta-Analysis. *Sci Rep.* 2015 Oct 1;5:14698. doi: 10.1038/srep14698
16. Gruenberg J, Manivel JC, Gupta P, Dykoski R, Mesa H. Fatal acute cardiac vasculopathy during cisplatin-gemcitabine-bevacizumab (CGB) chemotherapy for advanced urothelial carcinoma. *J Infect Chemother.* 2015 Sep 27. pii: S1341-321X(15)00198-1. doi: 10.1016/j.jiac.2015.08.015.
17. Kaneko E, Niwa R. Optimizing therapeutic antibody function: progress with Fc domain engineering. *BioDrugs.* 2011;25(1):1-11.
18. Wong ET, Lok E, Swanson KD. Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation. *Cancer Med.* 2015;4(3):383-91.
19. Salgia R, Patel P, Bothos J, Yu W, Eppler S, Hegde P, Bai S, Kaur S, Nijem I, Catenacci DV, Peterson A, Ratain MJ, Polite B, Mehnert JM, Moss RA Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. *Clin Cancer Res.* 2014;20(6):1666-75.
20. Wang H, Shi J, Wang Q, Li H, Cai K, Hou X, Li T, Zhong Q, Yu D. Assessment of the pre-clinical immunogenicity of a new VEGF receptor Fc-fusion protein FP3 with ELISA and BIACORE. *Cancer Immunol Immunother.* 2010;59(2):239-46.